Palisade Bio Stock Today
| PALI Stock | USD 1.04 0.01 0.97% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Palisade Bio is trading at 1.04 as of the 16th of February 2025. This is a 0.97 percent increase since the beginning of the trading day. The stock's open price was 1.03. Palisade Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of November 2024 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of December 2006 | Category Healthcare | Classification Health Care |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. The company has 2.77 M outstanding shares of which 136.96 K shares are at this time shorted by private and institutional investors with about 0.15 trading days to cover. More on Palisade Bio
Moving together with Palisade Stock
Moving against Palisade Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Palisade Stock Highlights
| CEO Director | J Finley | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPalisade Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Palisade Bio's financial leverage. It provides some insight into what part of Palisade Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Palisade Bio (PALI) is traded on NASDAQ Exchange in USA. It is located in 7750 El Camino Real, Carlsbad, CA, United States, 92009 and employs 9 people. Palisade Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.08 M. Palisade Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.77 M outstanding shares of which 136.96 K shares are at this time shorted by private and institutional investors with about 0.15 trading days to cover.
Palisade Bio currently holds about 5 M in cash with (11.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23.
Check Palisade Bio Probability Of Bankruptcy
Ownership AllocationRoughly 91.86 pct. of Palisade Bio outstanding shares are held by general public with 0.79 % owned by insiders and only 7.35 (%) by third-party entities.
Check Palisade Ownership Details
Palisade Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-09-30 | 52 K | |
| Jpmorgan Chase & Co | 2024-09-30 | 16.4 K | |
| Tower Research Capital Llc | 2024-09-30 | 1.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 140 | |
| Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 100.0 | |
| Ubs Group Ag | 2024-09-30 | 31.0 | |
| Wells Fargo & Co | 2024-09-30 | 21.0 | |
| Bank Of America Corp | 2024-09-30 | 9.0 |
Palisade Bio Historical Income Statement
Palisade Stock Against Markets
Palisade Bio Corporate Management
| Joerg Heyer | Head Medicine | Profile | |
| Ryker Willie | Senior Controller | Profile | |
| Sharon McBrayer | Director Operations | Profile | |
| Mitchell MD | Chief Officer | Profile | |
| Robert McRae | VP Devel | Profile | |
| MD FAAAAI | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.